This retrospective case series demonstrates the combination of 0.05% atropine with MiSight^® 1 day (Cooper vision, Sar Ramon, CA, USA) in rapid progression of myopia of 4 children. MiSight^® 1 day is a peripheral defocus, center-distance soft contact lens and is effective at controlling moderate progression of myopia during the course of 1 year. The current case series included 2 females and 2 males with an average age of 9.68 ± 0.26 years and an average axial length of 24.81 ± 0.92 mm. Their myopic progression during the previous year was −1.45 ± 0.27 D. The children had not attempted any myopia control thus far. This relatively high increase prompted a combination treatment of daily instillation of 0.05% atropine and MiSight, a daily replacement soft contact lens. Cycloplegic refraction and a slit-lamp evaluation were performed every 6 months to confirm no adverse reactions or staining was present. The 8-item contact lens dry eye questionnaire (CLDEQ-8) score of these children was 10.66 ± 1.52. The average myopia progression at the end of 1 year decreased to −0.41 ± 0.11 D, and the average axial length increase was 0.28 ± 0.08 mm. To the best of the authors’ knowledge, this is the first published study showing a combination of 0.05% atropine and peripheral defocus soft contact lenses indicating efficacy at controlling moderate myopia progression.
Case Rep Ophthalmol 2021;12:875–881

中文翻译：

---

近视快速进展的治疗：病例系列与文献综述

该回顾性病例系列展示了 0.05% 阿托品与 MiSight ^® 1 天（Cooper vision, Sar Ramon, CA, USA）联合治疗 4 名儿童近视的快速进展。米视^®1 day 是一种周边散焦、中心距软性隐形眼镜，可有效控制 1 年期间近视的中度进展。当前病例系列包括 2 名女性和 2 名男性，平均年龄为 9.68 ± 0.26 岁，平均轴向长度为 24.81 ± 0.92 mm。他们在前一年的近视进展为 -1.45 ± 0.27 D。到目前为止，孩子们还没有尝试过任何近视控制。这种相对较高的增长促使每日滴注 0.05% 阿托品和 MiSight（一种每日更换软性隐形眼镜）的联合治疗。每 6 个月进行一次散瞳验光和裂隙灯评估，以确认没有不良反应或染色存在。这些儿童的 8 项隐形眼镜干眼问卷 (CLDEQ-8) 得分为 10.66 ± 1.52。1 年末的平均近视进展降低至 -0.41 ± 0.11 D，平均轴向长度增加为 0.28 ± 0.08 mm。据作者所知，这是首次发表的研究显示 0.05% 阿托品和周边散焦软性隐形眼镜的组合表明在控制中度近视进展方面的功效。
Case Rep Ophthalmol 2021；12:875–881